2025
A plain language summary of the ASCERTAIN trial: oral decitabine and cedazuridine versus intravenous decitabine for MDS or CMML
Garcia-Manero G, McCloskey J, Griffiths E, Yee K, Zeidan A, Al-Kali A, Deeg H, Sabloff M, Keating M, Zhu N, Gabrail N, Fazal S, Maly J, Odenike O, DeZern A, O'Connell C, Roboz G, Busque L, Buckstein R, Amin H, Leber B, Shastri A, Oganesian A, Keer H, Azab M, Savona M. A plain language summary of the ASCERTAIN trial: oral decitabine and cedazuridine versus intravenous decitabine for MDS or CMML. Future Oncology 2025, 21: 929-941. PMID: 40051275, PMCID: PMC11938952, DOI: 10.1080/14796694.2025.2468578.Peer-Reviewed Original ResearchChronic myelomonocytic leukemiaAcute myeloid leukemiaIntravenous decitabineMyelodysplastic syndromeDEC-COral decitabineSide effectsRed blood cell transfusionPhase 3 clinical trialsMedian overall survivalTreatment-related deathsBlood cell transfusionDays of treatmentTransfusion independenceOverall survivalCell transfusionDecitabine groupMyelomonocytic leukemiaMyeloid leukemiaOral medicineDecitabineQuality of lifeReceiving treatmentTaking treatmentCedazuridineAcceptability of long-acting antiretroviral therapy among people living with HIV who use drugs in Vancouver, Canada: A qualitative study
Chayama K, Ng C, Brohman I, Mansoor M, Small W, Philbin M, Collins A, McNeil R. Acceptability of long-acting antiretroviral therapy among people living with HIV who use drugs in Vancouver, Canada: A qualitative study. PLOS ONE 2025, 20: e0319010. PMID: 40019916, PMCID: PMC11870339, DOI: 10.1371/journal.pone.0319010.Peer-Reviewed Original ResearchConceptsAdherence to antiretroviral therapyLong-acting antiretroviral therapyLA-ARTAntiretroviral therapySuboptimal adherence to antiretroviral therapyAdherence barriersProspective cohort studySuboptimal ART adherenceAdverse side effectsPill burdenTreatment optionsSubstance useCohort studyART adherenceTreatment advancesSide effectsTreatment changesPLHIVTreatment approachesTherapyCredible sources of informationPopulation-level benefitsDrugHIVSocial-structural inequitiesMoving beyond desensitization to tolerance in food allergy
Flom J, Shreffler W, Perrett K. Moving beyond desensitization to tolerance in food allergy. The Journal Of Allergy And Clinical Immunology In Practice 2025 PMID: 40010566, DOI: 10.1016/j.jaip.2025.02.014.Peer-Reviewed Original ResearchManagement of IgE-mediated food allergyFood allergyIgE-mediated food allergyStages of clinical developmentSide effect profileMode of deliveryGoal of therapeuticsSustained unresponsivenessDosing regimensDose protocolProactive therapyAllergen-specificClinical developmentActive therapyPatient populationSide effectsTherapyPassive therapyPatient-specificDesensitizationClinical contextPatientsDoseAllergyDegree of protectionMisoprostol administration mimicking a febrile transfusion reaction
Yurtsever N, Snyder E. Misoprostol administration mimicking a febrile transfusion reaction. Transfusion 2025, 65: 643-646. PMID: 39907501, DOI: 10.1111/trf.18150.Peer-Reviewed Original ResearchConceptsFebrile nonhemolytic transfusion reactionsTransfusion reactionsBlood culturesSynthetic prostaglandin E1 analogueThermogenic effectAdministration of misoprostolProstaglandin E1 analogueRed cell transfusionTransfusion medicineFebrile transfusion reactionsNonhemolytic transfusion reactionsG1P0 femaleMisoprostol administrationCell transfusionE1 analogueChart reviewSerological workupCase reportDifferential diagnosisEnhance patient satisfactionMisoprostolTransfusionUterotonic propertiesSerological findingsSide effectsP-1415. Social Determinants of Health and Side Effects Significantly Predict Pre-Exposure Prophylaxis (PrEP) Preferences for Every 2 Month Long-Acting Injectable vs. Daily Oral PrEP among Cisgender Women in the United States and the Dominican Republic
Kerrigan D, Scott R, O’Rourke A, Galai N, Karver T, Davis W, Metzner A, Oglesby A, Moriarty P, Taggart T, Barrington C, Gomez H, Perez M, Donastorg Y. P-1415. Social Determinants of Health and Side Effects Significantly Predict Pre-Exposure Prophylaxis (PrEP) Preferences for Every 2 Month Long-Acting Injectable vs. Daily Oral PrEP among Cisgender Women in the United States and the Dominican Republic. Open Forum Infectious Diseases 2025, 12: ofae631.1590. PMCID: PMC11777370, DOI: 10.1093/ofid/ofae631.1590.Peer-Reviewed Original ResearchPre-exposure prophylaxisLong-actingFemale sex workersSocial determinantsCisgender womenSocial determinants of healthHIV diagnosis ratesDaily oral PrEPDeterminants of healthBlack cisgender womenLow pre-exposure prophylaxisCross-sectional surveyOral PrEPUnited StatesHIV disparitiesWhite cisgender womenHIV inequitiesSide effectsIncreased oddsDiagnosis rateHIVPrEP preferencesDominican RepublicPrEPSex workersAntidopaminergic medications in Huntington's disease
Tan A, Geva M, Goldberg Y, Schuring H, Sanson B, Rosser A, Raymond L, Reilmann R, Hayden M, Anderson K. Antidopaminergic medications in Huntington's disease. Journal Of Huntington's Disease 2025, 14: 16-29. PMID: 39973394, DOI: 10.1177/18796397241304312.Peer-Reviewed Original ResearchConceptsAntidopaminergic medicationsSymbol Digit Modalities TestHuntington's diseaseComposite Unified Huntington’s Disease Rating Scale,Unified Huntington's Disease Rating ScaleExtrapyramidal symptomsWord readingHuntington's Disease Rating ScaleVMAT2 inhibitorsBehavioral impairmentsBehavioral disordersCognitive dysfunctionCognitive functionRating ScaleADM useDisease Rating ScaleHD symptomsTotal Functional CapacityModal testingMotor disturbancesFunctional impairmentProgressive neurodegenerative disorderMounting body of evidenceSide effectsBody of evidenceAnti-Syndecan 2 Antibody Treatment Reduces Edema Formation and Inflammation of Murine Laser-Induced CNV.
Corti F, Locri F, Plastino F, Perrotta P, Zsebo K, Ristori E, Yin X, Song E, André H, Simons M. Anti-Syndecan 2 Antibody Treatment Reduces Edema Formation and Inflammation of Murine Laser-Induced CNV. Translational Vision Science & Technology 2025, 14: 10. PMID: 39792057, PMCID: PMC11730891, DOI: 10.1167/tvst.14.1.10.Peer-Reviewed Original ResearchConceptsAge-related macular degenerationLaser-induced choroidal neovascularizationAnti-VEGF therapyTransendothelial electrical resistanceVEGF-A activityChoroidal neovascularizationIntravitreal injectionRetinal lesionsLong-term anti-VEGF therapyMurine laser-induced choroidal neovascularizationNeovascular age-related macular degenerationWet age-related macular degenerationAlteration of visual acuityIntravitreal anti-VEGF therapySide effectsLocal intravitreal injectionReduced edema formationSuppression of edemaRelated side effectsPermeability in vitroEndothelial cell junctionsNeovascular AMDVisual acuityAssessed in vitroMacular degenerationTau is a receptor with low affinity for glucocorticoids and is required for glucocorticoid-induced bone loss
Fu W, Chen M, Wang K, Chen Y, Cui Y, Xie Y, Lei Z, Hu W, Sun G, Huang G, He C, Fretz J, Hettinghouse A, Liu R, Cai X, Zhang M, Chen Y, Jiang N, He M, Wiznia D, Xu H, Chen Z, Chen L, Tang K, Zhou H, Liu C. Tau is a receptor with low affinity for glucocorticoids and is required for glucocorticoid-induced bone loss. Cell Research 2025, 35: 23-44. PMID: 39743632, PMCID: PMC11701132, DOI: 10.1038/s41422-024-01016-0.Peer-Reviewed Original ResearchConceptsGC-induced osteoporosisBone lossInflammatory arthritisAdverse effects of dexamethasoneGlucocorticoid-induced bone lossHigh-dose dexamethasoneEffect of dexamethasoneFDA-approved drug librarySynthetic GCTreat inflammatory arthritisImmunosuppressive drugsPrescribed anti-inflammatoryGC receptorCombinatorial administrationSide effectsLow affinityGlucocorticoidOsteoporosisDexamethasoneReceptorsAdverse effectsBinding receptorsAnti-inflammatoryDrug libraryTau deficiency
2024
Efficacy of GABA aminotransferase inactivator OV329 in models of neuropathic and inflammatory pain without tolerance or addiction
Wirt J, Ferreira L, Jesus C, Woodward T, Oliva I, Xu Z, Crystal J, Pepin R, Silverman R, Hohmann A. Efficacy of GABA aminotransferase inactivator OV329 in models of neuropathic and inflammatory pain without tolerance or addiction. Proceedings Of The National Academy Of Sciences Of The United States Of America 2024, 122: e2318833121. PMID: 39793055, PMCID: PMC11725897, DOI: 10.1073/pnas.2318833121.Peer-Reviewed Original ResearchConceptsComplete Freund's adjuvantInflammatory painMechanical hypersensitivityAntinociceptive efficacyGlutamate levelsInjection of complete Freund's adjuvantConditioned place preference assayPaclitaxel-induced mechanical hypersensitivitySpinal site of actionSide effectsEnhancement of GABAergic transmissionChemotherapeutic agent paclitaxelPaclitaxel-induced increaseCompared to morphineLumbar spinal cordIncreased endogenous GABA levelsReduced glutamate levelsNeuropathic nociceptionSite of actionGABAergic transmissionAnalgesic strategiesPathological painGABAergic inhibitionSpinal sitesAbuse liabilityPractice Advisory for Postoperative Pain Management of Thoracic Surgical Patients: Executive Summary: A Report From the Society of Cardiovascular Anesthesiologists
Makkad B, Heinke T, Sheriffdeen R, Meng M, Kachulis B, Grant M, Popescu W, Brodt J, Khatib D, Wu C, Kertai M, Bollen B. Practice Advisory for Postoperative Pain Management of Thoracic Surgical Patients: Executive Summary: A Report From the Society of Cardiovascular Anesthesiologists. Journal Of Cardiothoracic And Vascular Anesthesia 2024, 39: 880-888. PMID: 39864980, DOI: 10.1053/j.jvca.2024.12.003.Peer-Reviewed Original ResearchThoracic surgical patientsPostoperative pain managementPostoperative painPain controlSurgical populationSurgical patientsOpioid-related side effectsRisk of respiratory complicationsPersistent postoperative painPre-existing co-morbiditiesPractice advisorySociety of Cardiovascular AnesthesiologistsAnalgesic regimenRespiratory complicationsSignificant painPerioperative providersPain managementCo-morbiditiesNormal respiratory mechanicsPainSide effectsImpaired recoveryRespiratory mechanicsPatientsCardiovascular AnesthesiologistsParent Perspectives on Nirsevimab for Their Newborn.
Hinderstein S, Aragona E, Loyal J. Parent Perspectives on Nirsevimab for Their Newborn. Pediatrics 2024, 154 PMID: 39587878, DOI: 10.1542/peds.2024-067532.Peer-Reviewed Original ResearchConceptsRespiratory syncytial virusRespiratory syncytial virus prophylaxisRSV disease severityMaternal RSV vaccineHealth Belief ModelHealthy newbornsRSV vaccineRSV infectionParents of newbornsNewborn unitSyncytial virusNirsevimabSide effectsNewbornsBelief ModelPediatric hospitalMonoclonal antibodiesDisease severityCOVID-19 vaccineProphylaxisVaccineIncreasing overall awarenessInfantsPediatrician's recommendationPositively influence decisionMRI after focal therapy for prostate cancer: what radiologists must know?
Jalilianhasanpour R, Arora S, Mansoori B, Raman S, Greenwood B, Sprenkle P, Schade G, Camacho M, Hosseini N, Westphalen A. MRI after focal therapy for prostate cancer: what radiologists must know? Abdominal Radiology 2024, 1-20. PMID: 39542951, DOI: 10.1007/s00261-024-04670-5.Peer-Reviewed Original ResearchIn-human clinical experience with direct stick embolization of low-flow vascular malformations using a mammalian target of rapamycin inhibitor
Restrepo-Espinosa V, Lee A, Prozora S, Patel P, Nassiri N. In-human clinical experience with direct stick embolization of low-flow vascular malformations using a mammalian target of rapamycin inhibitor. Journal Of Vascular Surgery Venous And Lymphatic Disorders 2024, 13: 101997. PMID: 39515753, DOI: 10.1016/j.jvsv.2024.101997.Peer-Reviewed Original ResearchLow-flow vascular malformationsMTOR inhibitorsClinical successVascular malformationsSide effectsLocalized intravascular coagulopathyOral aphthous ulcersKlippel-Trenaunay syndromeLymphatic malformationsVenous malformationsRe-interventionDelayed complicationsNon-syndromicTechnical successAphthous ulcersIntravascular coagulopathyD-dimerEndovascular treatmentSystemic exposureAdjunctive therapySystemic toxicityFrequent bloodMalformationsSelf-limitingMTOR inhibitionBuprenorphine Knowledge and Attitudes Among Sickle Cell Disease Providers
Nguemeni Tiako M, Afranie-Sakyi J, Van Doren L, Vasquez K, Calhoun C. Buprenorphine Knowledge and Attitudes Among Sickle Cell Disease Providers. Blood 2024, 144: 2442-2442. DOI: 10.1182/blood-2024-206368.Peer-Reviewed Original ResearchSickle cell diseaseChronic painOpioid analgesicsSide effectsX-waiverPain managementAdequate analgesiaRespiratory depressionTraditional opioidsOff-labelSickle cell disease providerBuprenorphine formulationsImproving provider knowledgeFDA approvalSurvey of providersRisk of respiratory depressionCross-sectional surveyEffective opioid analgesicMedical education opportunitiesOpioid-induced hyperalgesiaSickle cell disease patientsCompared to other opioidsMorphine milligram equivalentsOpioid side effectsAbuse-deterrent technologyMolecular and Clinical Determinants of CAR-T Therapy Response in DLBCL
Thakkar D, Hill B, Kositsky R, Tian S, Biral L, Russell V, Dave T, Love C, Roth C, McKinney M, Galal A, Neff J, Mian A, Kendall E, Ondrejka S, Chiaramonte M, Bhagat G, Ofori K, Reshef R, Kovach A, Sethi T, Mason E, Bhaskar S, Oluwole O, McCall C, Pallas C, Ghosh N, Ferdman R, Chen G, Hernandez-Ilizaliturri F, Zurko J, Cunningham A, Shah N, Hu B, Stephens D, Ghosh M, Bailey N, Patel K, Pagel J, Kannan K, Hsi E, Vaidya R, Ip A, Goy A, Kambhampati S, Ohgami R, Andreadis C, Gordillo C, Just B, Cohen J, Baim A, Barbello J, Cavallone E, Bachanova V, Laschen M, Teferra A, Lorcy F, Lamure S, Cartron G, Dardalhon V, Naresh K, Czader M, Reddy A, Thacker E, Parker C, Happ L, Dave S. Molecular and Clinical Determinants of CAR-T Therapy Response in DLBCL. Blood 2024, 144: 3409. DOI: 10.1182/blood-2024-199758.Peer-Reviewed Original ResearchDiffuse large B-cell lymphomaCAR-T-cell-related encephalopathy syndromeProgression-free survivalCAR-T therapyDiffuse large B-cell lymphoma patientsActivated B-cell typeInternational Prognostic IndexChimeric antigen receptorCAR-TCytokine release syndromeOverall survivalFavorable prognosisPrognostic scoreB cellsAssociated with worse progression-free survivalAssociated with progression-free survivalSubtype of diffuse large B-cell lymphomaHigher International Prognostic IndexInternational Prognostic Index scoreAchievement of complete remissionLarge B-cell lymphomaTumors prior to treatmentSide effectsMultiple extranodal sitesSurface markers CD19Dexamethasone Targets E2F4 to Induce Erythroid Progenitor Renewal
Papoin J, Schulz V, Khan F, Barnes B, Lipton J, Steiner L, Narla M, Gallagher P, Blanc L. Dexamethasone Targets E2F4 to Induce Erythroid Progenitor Renewal. Blood 2024, 144: 1076. DOI: 10.1182/blood-2024-211687.Peer-Reviewed Original ResearchDiamond-Blackfan anemiaCD34+ cellsErythroid progenitorsSteroid responsivenessExpression of E2F4Peripheral bloodBone marrowE2F4 expressionDex treatmentCultured CD34+ cellsInherited bone marrow failure syndromeMechanisms of steroid responseSide effectsBone marrow failure syndromesDiamond-Blackfan anemia patientsBone marrow erythroid progenitorsIncreased expressionMechanisms of corticosteroid actionAssociated with side effectsIncreased risk of infectionMarrow failure syndromesResponse to steroidsGene promoterSerum-free culture systemMarrow erythroid progenitorsBuprenorphine & Sickle Cell: How Pediatric and Adult Providers Differ in Prescribing Habits and Evolving Pain Management Styles
Afranie-Sakyi J, Tiako M, Vasquez K, Van Doren L, Calhoun C. Buprenorphine & Sickle Cell: How Pediatric and Adult Providers Differ in Prescribing Habits and Evolving Pain Management Styles. Blood 2024, 144: 3628. DOI: 10.1182/blood-2024-194039.Peer-Reviewed Original ResearchSickle cell disease providerSCD-related painSickle cell diseaseAdult providersOpioid use disorderPrescribing buprenorphineX-waiverOpioid agonistsPain managementChronic painPrescribing habitsPediatric providersInitiate buprenorphineAdvanced practice providersSCD agesHigh volume of patientsPain management guidelinesSide effectsOptimal pain managementDose-dependent adverse effectsDecreased quality of lifeCross-sectional studyPartial opioid agonistQuality of lifeChronic hemolytic anemiaAssociation Between Chemotherapy-Induced Peripheral Neuropathy and Low Anterior Resection Syndrome
Linhares S, Schultz K, Coppersmith N, Esposito A, Leeds I, Pantel H, Reddy V, Mongiu A. Association Between Chemotherapy-Induced Peripheral Neuropathy and Low Anterior Resection Syndrome. Cancers 2024, 16: 3578. PMID: 39518019, PMCID: PMC11545659, DOI: 10.3390/cancers16213578.Peer-Reviewed Original ResearchLow anterior resection syndromeChemotherapy-induced peripheral neuropathyAnterior resection syndromeSystemic therapyRectal cancerPeripheral neuropathyAssociated with low anterior resection syndromeRetrospective review of patientsPlatinum-based chemotherapy agentsLow anterior resectionReview of patientsSphincter-preserving surgeryRectal cancer treatmentNeoadjuvant chemoradiationTumor distanceAnal vergeAnterior resectionRetrospective reviewChemotherapy-inducedChemotherapy agentsSide effectsCancer treatmentDebilitating conditionPatientsCIPNFever and Therapeutic Hypothermia
Subramaniam T, Parasram M, Barnes E, Picard J, Sheth K. Fever and Therapeutic Hypothermia. 2024, 301-313. DOI: 10.1007/978-3-031-62220-5_19.Peer-Reviewed Original ResearchTargeted temperature managementTherapeutic hypothermiaInduction of hypothermiaPost-cardiac arrestNeurological diseasesCritical care settingManagement of feverNeurocritical care unitNeurologically injured patientsCare settingsSide effectsCare unitInjured brainFeverTemperature managementTherapeutic purposesPatientsHypothermiaPredicting Radiation-Induced Acute Toxicity in Breast Cancer Patients: A Radiogenomic Approach
Wei S, Zhang Y, Sowmiyanarayanan S, Yehia Z, Jan I, Yue N, Haffty B, Nie K. Predicting Radiation-Induced Acute Toxicity in Breast Cancer Patients: A Radiogenomic Approach. International Journal Of Radiation Oncology • Biology • Physics 2024, 120: e341. DOI: 10.1016/j.ijrobp.2024.07.752.Peer-Reviewed Original ResearchBreast cancer patientsRadiation dermatitisSide effectsCancer patientsBreast cancer patients treated with radiationRadiogenomic approachCancer patients treated with radiationRadiation-induced acute toxicityPatients treated with radiationRadiomic featuresSingle nucleotide polymorphismsAcute radiation dermatitisBreast-conserving surgeryRadiation side effectsPeripheral blood samplesTotal radiation dosePersonalized treatment strategiesGenetic statusRadiation therapyMammographic patternsRadiomic texture featuresTherapy side effectsClinical parametersRetrospective studyClinical features
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply